CJC-1295 (no DAC) vs Tesamorelin
How CJC-1295 (no DAC) and Tesamorelin compare on research category, evidence tier, regulatory status, and reported side effects.
The verdict
Both raise growth hormone through the GHRH pathway, but they sit at very different evidence levels. Tesamorelin is FDA-approved (specifically for excess abdominal fat in HIV-associated lipodystrophy) and carries real human trial data, so it is the one with a documented clinical record. CJC-1295 is a research-use-only compound with far thinner human evidence, mostly early-stage. On proof and regulatory standing Tesamorelin is the far better-characterized of the two; CJC-1295 shows up mainly in research-use discussion, not because it has comparable clinical support.
CJC-1295 (the 'no-DAC' version) is the partner peptide to Ipamorelin. Together they push a stronger natural GH pulse. Always paired, never run alone in this protocol.
Tesamorelin is an FDA-approved GH-axis peptide that specifically targets visceral fat, the deep belly fat around organs. Daily injection. Slow burn, but the visceral fat reduction is well-documented.
Which one should you pick?
Pick CJC-1295 (no DAC) if users stacking with ipamorelin (the canonical pair) or people wanting gh benefits while preserving the natural pulse rhythm.
Pick Tesamorelin if users targeting visceral (deep abdominal) fat specifically or older adults wanting gh-axis support without hgh.
Still torn between CJC-1295 (no DAC) and Tesamorelin?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.